{"altmetric_id":7372363,"counts":{"readers":{"mendeley":1,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["TrueDiagnostics"],"posts_count":1}},"selected_quotes":["Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in \u2026"],"citation":{"altmetric_jid":"4f6fa6113cf058f610006efa","doi":"10.1158\/1078-0432.ccr-16-0645","endpage":"2596","first_seen_on":"2016-05-13T10:18:21+00:00","funders":["niehs"],"issns":["1557-3265","1078-0432"],"issue":"10","journal":"Clinical Cancer Research","last_mentioned_on":1463113850,"links":["http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1&GrsVU","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1&YKyG","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1&IaVR3","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1&0GE","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1&F7r1m","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1&AfEb","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.short?rss=1&JLj","http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.large.jpg?rss=1&HMVut"],"pdf_url":"http:\/\/clincancerres.aacrjournals.org\/content\/22\/10\/2596.full.pdf","pmid":"27179115","pubdate":"2016-05-15T00:00:00+00:00","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Health Sciences","Medicine","Life Sciences","Biochemistry, Genetics and Molecular Biology"],"startpage":"2596","subjects":["neoplasms"],"title":"Correction: A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer","type":"article","volume":"22","mendeley_url":"http:\/\/www.mendeley.com\/research\/correction-firstinhuman-phase-i-study-oral-p38-mapk-inhibitor-ralimetinib-ly2228820-dimesylate-patie"},"altmetric_score":{"score":1,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":1},"context_for_score":{"all":{"total_number_of_other_articles":7693476,"mean":6.6032853252866,"rank":3984720,"this_scored_higher_than_pct":28,"this_scored_higher_than":2162253,"rank_type":"exact","sample_size":7693476,"percentile":28},"similar_age_3m":{"total_number_of_other_articles":269121,"mean":11.424091773186,"rank":146149,"this_scored_higher_than_pct":35,"this_scored_higher_than":96618,"rank_type":"exact","sample_size":269121,"percentile":35},"this_journal":{"total_number_of_other_articles":5170,"mean":5.6443141806926,"rank":3433,"this_scored_higher_than_pct":24,"this_scored_higher_than":1242,"rank_type":"exact","sample_size":5170,"percentile":24},"similar_age_this_journal_3m":{"total_number_of_other_articles":182,"mean":9.5699447513812,"rank":166,"this_scored_higher_than_pct":4,"this_scored_higher_than":9,"rank_type":"exact","sample_size":182,"percentile":4}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}},"mendeley":{"by_status":{"Student  > Postgraduate":1},"by_discipline":{"Medicine and Dentistry":1}}},"geo":{"twitter":{"US":1}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/TrueDiagnostics\/statuses\/730978587961131009","license":"gnip","citation_ids":[7372363],"posted_on":"2016-05-13T04:30:50+00:00","author":{"name":"Jerry Lee","url":"http:\/\/www.truediag.com","image":"https:\/\/pbs.twimg.com\/profile_images\/567483990097936384\/6uKJglvi_normal.jpeg","description":"We specialize in providing quick & simple quantitative test systems designed for point-of-care monitoring. Test results in minutes not days..","id_on_source":"TrueDiagnostics","tweeter_id":"317232537","geo":{"lt":32.71533,"ln":-117.15726,"country":"US"},"followers":382},"tweet_id":"730978587961131009"}]}}